The global photodynamic therapy market is valued at an estimated US$ 1.63 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 6.1%, reaching approximately US$ 2.93 billion by the end of 2034. Photodynamic Therapy Market is an up-and-coming and fast-growing modality of treatment applied to a range of medical conditions; it is best represented in oncology, dermatology, and ophthalmology. It exploits the principle of photosensitizing agents combined with light to generate reactive oxygen species that destroy the target cells. The PDT market is growing significantly, driven by its minimal invasiveness, high precision, and low side effects compared to conventional therapies.
Get Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=10179
Market Dynamics
Driving Factors
Rising Cases of Cancer and Skin Disorders: The increase in cases of cancers, such as non-melanoma skin cancer and actinic keratosis, are some of the major driving factors for the PDT market. According to the World Health Organization, skin cancer is estimated to be the most common form of cancer globally, which calls for effective treatment measures such as PDT.
Improved Technologies: The new light delivery systems, such as LEDs and laser technologies, have increased the efficacy and safety of PDT. The development of new photosensitizers with improved selectivity and reduced side effects is also boosting market growth.
Growing Preference for Non-Invasive Procedures: Patients and health professionals are increasingly trending toward non-invasive or minimally invasive treatments. Since PDT is a non-surgical method with lesser complications and faster recovery time, it becomes one of the preferred choices for treating various conditions.
Government Support and Funding: Recognizing the potential of PDT to offer inexpensive, effective treatment solutions, a host of governments and health organizations are funding research and development. Government support is timely in helping to accelerate the adoption and advancement of PDT technologies.
Restraining Factors
High Cost of Treatment: While the advantages of PDT exist, the high cost associated with photosensitizers and light delivery equipment can easily become a barrier to its wide-scale adoption in low- and middle-income countries.
Limited Awareness and Expertise: There is a need for raising awareness and training among health professionals on the use and advantages of PDT. Lack of expertise has limited its application in clinical practice.
Side Effects and Contraindications: Though PDT is comparatively safe, there exists the problem of photosensitivity, wherein patients need to avoid sunlight for a certain period of time after the treatment. Such inconvenience becomes an inconvenience factor and dissuades a segment of its prospective clientele from opting for PDT.
Key Companies Profiled
LitePharmTech
Shenzhen Hytera Communications Corporation
Simphotek, Inc.
CBIO Limited
Avon Products, Inc.
Sun Pharmaceuticals Industries Ltd.
Quest PharmaTech, Inc.
Theralase Technologies Inc.
Biofrontera AG.
Future Outlook
The future of photodynamic therapy does indeed look bright with continuous technological development and growing adoption in many medical fields. As awareness increases and prices come down in the near future, PDT will turn out to be a mainstream choice for treating a whole host of diseases and injuries, hence offering the patients a much safer and more effective option from the traditional modalities of treatment.
Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=RC&rep_id=10179
Competitive Landscape
In January 2024, Theralase Technologies Inc., a pharmaceutical company, announced the results from its Phase II clinical research on non-muscle invasive bladder cancer. The study reported complete response rates of 54% at 6 months, 38% at 12 months, and 37% at 15 months, surpassing the recommendations of the International Bladder Cancer Group.
In December 2023, Biofrontera AG's Photodynamic Therapy (PDT) treatment protocol was granted a patent in the United States. This innovative approach utilizes a photosensitizer and two light exposures at various wavelengths, reinforcing Biofrontera's commitment to pioneering PDT strategies. Additionally, the patent safeguards Biofrontera's medication Ameluz against generic competition.
In August 2023, ImPact Biotech and Maastricht University formed a collaboration to advance research on eye treatments targeting pathological myopia, known as myopic macular degeneration (MMD). Utilizing ImPact's Padeliporfin vascular targeted photodynamic therapy (VTP) technology, this partnership aims to develop therapies to halt the progression of MMD.
About Fact.MR :
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.
Contact:
US Sales Office
11140 Rockville Pike
Suite 400 Rockville, MD 20852
United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Sales Team: sales@factmr.com